Story perspectives

U.S. Revives Lawsuit Against Drugmakers Over Pricing Fraud

3/20/2026

Summary

Story summary

The U.S. government is working with pharmaceutical companies to implement U.S. President Donald Trump’s most-favored-nation drug pricing policy, per HHS chief counsel Chris Klomp, to lower U.S. drug costs.
A U.S. appeals court revived a whistleblower lawsuit against four major drugmakers for allegedly defrauding the government by overcharging for medications.
The case underscores ongoing pharmaceutical issues, including GSK actions that have raised barriers to patient access.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established a drug benefit for seniors, leading to projected spending of $724 billion over ten years. Despite initial successes, ongoing challenges with drug affordability persist, as seen in recent whistleblower lawsuits against pharmaceutical companies. These issues underscore the need for reform in the pharmaceutical industry and highlight the complexities of Medicare Part D's implementation since its launch in 2006.

1 of 2

Story summary

The U.S. government is working with pharmaceutical companies to implement U.S. President Donald Trump’s most-favored-nation drug pricing policy, per HHS chief counsel Chris Klomp, to lower U.S. drug costs.
A U.S. appeals court revived a whistleblower lawsuit against four major drugmakers for allegedly defrauding the government by overcharging for medications.
The case underscores ongoing pharmaceutical issues, including GSK actions that have raised barriers to patient access.

1 / 2